Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 17/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982202 | 0.85 | ESR1 (0.74) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL3925608 | 0.85 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3934241 | 0.84 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3922766 | 0.82 | ESR2 (1.00) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL3928809 | 0.82 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3933985 | 0.80 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3933824 | 0.79 | ESR1 (1.00) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3926652 | 0.79 | ESR2 (1.00) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL9622923 | 0.79 | ESR1 (0.72) | ESR1ESR2 | |
| SCHEMBL3933773 | 0.77 | ESR2 (0.89) | ESR1ESR2HSD17B1HSD17B2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| EP-1824478-A2 | NOVEL USES FOR ESTROGEN BETA AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2006065968-A2 | THE USES OF ESTROGEN BETA AGONISTS TO TREAT COGNITIVE DISEASES | WYETH (US) | 2006-06-22 | — | — | WO | claimed |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | WYETH (US) | 2006-06-22 | — | — | US | claimed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | claimed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | claimed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | claimed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | claimed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1824478-A2 | NOVEL USES FOR ESTROGEN BETA AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7067524-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | WYETH (US) | 2006-06-22 | — | — | US | disclosed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | MEWSHAW RICHARD E (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR1 2/4885ESR2 1/4885HSD17B1 160/4885 |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885HSD17B1 99/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR1 4/4885ESR2 5/4885HSD17B1 61/4885 |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR1 2/4885ESR2 1/4885HSD17B1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.